Trial Profile
Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Bronchiolo-alveolar adenocarcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms I-SABR
- 12 Sep 2023 Primary endpoint has been met. (4-year event-free survival (EFS; local/regional/distant recurrence, second primary, or death).)
- 12 Sep 2023 Results presented at the 24th World Conference on Lung Cancer
- 26 May 2023 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.